Education
About Us
Working with TipRanks
Follow Us
Climb Bio, Inc. (CLYM)
:CLYM
CLYM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $11.55
Previous CloseN/A
Volume51.97K
Average Volume (3M)260.26K
Market Cap
$86.37M
Enterprise Value-$29.33M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta0.31
Next Earnings
May 19, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding67,475,395
10 Day Avg. Volume130,516
30 Day Avg. Volume260,259
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1324.10
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside681.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Climb Bio News
PremiumCompany Announcements
Climb Bio Advances Clinical Trials and Expands Pipeline
PremiumCompany Announcements
Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases
---
Bulls Say, Bears Say
Bulls Say
FDA ClearanceThe company has received FDA clearance to initiate a Phase 2 study of budo in primary membranous nephropathy following compelling data from a Phase 1b trial.
Financial PositionCLYM reported a cash position of approximately $213 million, providing financial runway through 2027.
Pipeline DevelopmentCLYM's strategy involves addressing the high unmet medical need in IgAN and other B-cell mediated diseases with '116, which could drive more rapid, deeper, and durable inhibition of APRIL and pathogenic IgA.
Bears Say
Clinical TrialsPreclinical results for the subcutaneous formulation of budo are expected and the company plans to advance this program into the clinic.
Market CompetitionThe familiar antibody format and commercial scalability of budo offer an attractive option that balances efficacy and safety in the competitive CD19-targeting space.
---
Ownership Overview
8.53% Insiders
3.34% Mutual Funds
63.16% Other Institutional Investors
20.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLYM FAQ
What was Climb Bio, Inc.’s price range in the past 12 months?
Climb Bio, Inc. lowest stock price was $1.20 and its highest was $11.55 in the past 12 months.
What is Climb Bio, Inc.’s market cap?
Climb Bio, Inc.’s market cap is $86.37M.
When is Climb Bio, Inc.’s upcoming earnings report date?
Climb Bio, Inc.’s upcoming earnings report date is May 19, 2025 which is in 49 days.
How were Climb Bio, Inc.’s earnings last quarter?
Climb Bio, Inc. released its earnings results on Mar 25, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.02.
Is Climb Bio, Inc. overvalued?
According to Wall Street analysts Climb Bio, Inc.’s price is currently Undervalued.
Does Climb Bio, Inc. pay dividends?
Climb Bio, Inc. does not currently pay dividends.
What is Climb Bio, Inc.’s EPS estimate?
Climb Bio, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Climb Bio, Inc. have?
Climb Bio, Inc. has 67,475,395 shares outstanding.
What happened to Climb Bio, Inc.’s price movement after its last earnings report?
Climb Bio, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Climb Bio, Inc.?
Currently, no hedge funds are holding shares in CLYM
---
Climb Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (681.25% Upside)
$10.00 (681.25% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 612.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.28%
12-Months-Change
Fundamentals
Return on Equity
-46.26%
Trailing 12-Months
Asset Growth
96.60%
Trailing 12-Months
Company Description
Climb Bio, Inc.
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
---
CLYM Stock 12 Month Forecast
Average Price Target
$10.00
▲(681.25% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Leap Therapeutics
―
Bioxcel Therapeutics
―
Verrica Pharmaceuticals
―
Foghorn Therapeutics
―
ATAI Life Sciences
―
Best Analysts Covering CLYM
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-31.23%
reiterated a buy rating 7 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -31.23% per trade.
---